pdf.ilacprospektusu.com · intravenöz LD50 dežerleri slraswla 77 ve 83 mg/kg 'dlr. 5....
11
Transcript of pdf.ilacprospektusu.com · intravenöz LD50 dežerleri slraswla 77 ve 83 mg/kg 'dlr. 5....
![Page 1: pdf.ilacprospektusu.com · intravenöz LD50 dežerleri slraswla 77 ve 83 mg/kg 'dlr. 5. FARMAKOLO.JiK ÖZELLiKLER 5.1. Farmakodinamik özellikler Farmakoterapötik grup: H2-Reseptör](https://reader036.fdocument.pub/reader036/viewer/2022081409/6079071e6ad1173ec56c2ff2/html5/thumbnails/1.jpg)
![Page 2: pdf.ilacprospektusu.com · intravenöz LD50 dežerleri slraswla 77 ve 83 mg/kg 'dlr. 5. FARMAKOLO.JiK ÖZELLiKLER 5.1. Farmakodinamik özellikler Farmakoterapötik grup: H2-Reseptör](https://reader036.fdocument.pub/reader036/viewer/2022081409/6079071e6ad1173ec56c2ff2/html5/thumbnails/2.jpg)
![Page 3: pdf.ilacprospektusu.com · intravenöz LD50 dežerleri slraswla 77 ve 83 mg/kg 'dlr. 5. FARMAKOLO.JiK ÖZELLiKLER 5.1. Farmakodinamik özellikler Farmakoterapötik grup: H2-Reseptör](https://reader036.fdocument.pub/reader036/viewer/2022081409/6079071e6ad1173ec56c2ff2/html5/thumbnails/3.jpg)
![Page 4: pdf.ilacprospektusu.com · intravenöz LD50 dežerleri slraswla 77 ve 83 mg/kg 'dlr. 5. FARMAKOLO.JiK ÖZELLiKLER 5.1. Farmakodinamik özellikler Farmakoterapötik grup: H2-Reseptör](https://reader036.fdocument.pub/reader036/viewer/2022081409/6079071e6ad1173ec56c2ff2/html5/thumbnails/4.jpg)
![Page 5: pdf.ilacprospektusu.com · intravenöz LD50 dežerleri slraswla 77 ve 83 mg/kg 'dlr. 5. FARMAKOLO.JiK ÖZELLiKLER 5.1. Farmakodinamik özellikler Farmakoterapötik grup: H2-Reseptör](https://reader036.fdocument.pub/reader036/viewer/2022081409/6079071e6ad1173ec56c2ff2/html5/thumbnails/5.jpg)
![Page 6: pdf.ilacprospektusu.com · intravenöz LD50 dežerleri slraswla 77 ve 83 mg/kg 'dlr. 5. FARMAKOLO.JiK ÖZELLiKLER 5.1. Farmakodinamik özellikler Farmakoterapötik grup: H2-Reseptör](https://reader036.fdocument.pub/reader036/viewer/2022081409/6079071e6ad1173ec56c2ff2/html5/thumbnails/6.jpg)
![Page 7: pdf.ilacprospektusu.com · intravenöz LD50 dežerleri slraswla 77 ve 83 mg/kg 'dlr. 5. FARMAKOLO.JiK ÖZELLiKLER 5.1. Farmakodinamik özellikler Farmakoterapötik grup: H2-Reseptör](https://reader036.fdocument.pub/reader036/viewer/2022081409/6079071e6ad1173ec56c2ff2/html5/thumbnails/7.jpg)
![Page 8: pdf.ilacprospektusu.com · intravenöz LD50 dežerleri slraswla 77 ve 83 mg/kg 'dlr. 5. FARMAKOLO.JiK ÖZELLiKLER 5.1. Farmakodinamik özellikler Farmakoterapötik grup: H2-Reseptör](https://reader036.fdocument.pub/reader036/viewer/2022081409/6079071e6ad1173ec56c2ff2/html5/thumbnails/8.jpg)
![Page 9: pdf.ilacprospektusu.com · intravenöz LD50 dežerleri slraswla 77 ve 83 mg/kg 'dlr. 5. FARMAKOLO.JiK ÖZELLiKLER 5.1. Farmakodinamik özellikler Farmakoterapötik grup: H2-Reseptör](https://reader036.fdocument.pub/reader036/viewer/2022081409/6079071e6ad1173ec56c2ff2/html5/thumbnails/9.jpg)
![Page 10: pdf.ilacprospektusu.com · intravenöz LD50 dežerleri slraswla 77 ve 83 mg/kg 'dlr. 5. FARMAKOLO.JiK ÖZELLiKLER 5.1. Farmakodinamik özellikler Farmakoterapötik grup: H2-Reseptör](https://reader036.fdocument.pub/reader036/viewer/2022081409/6079071e6ad1173ec56c2ff2/html5/thumbnails/10.jpg)
![Page 11: pdf.ilacprospektusu.com · intravenöz LD50 dežerleri slraswla 77 ve 83 mg/kg 'dlr. 5. FARMAKOLO.JiK ÖZELLiKLER 5.1. Farmakodinamik özellikler Farmakoterapötik grup: H2-Reseptör](https://reader036.fdocument.pub/reader036/viewer/2022081409/6079071e6ad1173ec56c2ff2/html5/thumbnails/11.jpg)